Michael D Spain

US Patent:

7189516, Mar 13, 2007

Filed:

Aug 19, 2002

Appl. No.:

10/222867

Inventors:

James P. Mapes - Austin TX, US
James W. Jacobson - Austin TX, US
Harold N. Baker - Austin TX, US
Michael D. Spain - Austin TX, US

Assignee:

Luminex Corporation - Austin TX

International Classification:

G01N 33/53

US Classification:

435 71, 435 792, 435973, 436506, 436518, 436523, 436524

Abstract:

The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.

US Patent:

7455980, Nov 25, 2008

Filed:

Feb 13, 2007

Appl. No.:

11/674365

Inventors:

James P. Mapes - Austin TX, US
James W. Jacobson - Austin TX, US
Harold N. Baker - Austin TX, US
Michael D. Spain - Austin TX, US

Assignee:

Luminex Corporation - Austin TX

International Classification:

G01N 33/53

US Classification:

435 71, 435 792, 435 794, 436501, 436518, 436523, 436811

Abstract:

The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.

US Patent:

20010026920, Oct 4, 2001

Filed:

Feb 26, 2001

Appl. No.:

09/791894

Inventors:

Mark Chandler - Austin TX, US
Michael Spain - Austin TX, US

International Classification:

C12Q001/68
G01N033/53
G01N033/537
G01N033/543

US Classification:

435/006000, 435/007920, 436/518000

Abstract:

Internal standards and controls are provided for detecting and/or compensating for sources of measurement error in multiplexed diagnostic and genetic assays. The internal standards include subsets of particles comprising ligand binding partner specific for analytes of interest, each subset having a different known amount of ligand binding partner. Internal controls include subsets of particles comprising ligand binding partner chosen to provide information relating to high-dose hook effects, dilutional linearity, interfering assay factors, or sample or reagent omission.

US Patent:

20050079099, Apr 14, 2005

Filed:

Oct 12, 2004

Appl. No.:

10/961145

Inventors:

Michael Spain - Austin TX, US
Craig Benson - Austin TX, US
Mark Chandler - Austin TX, US
James Mapes - Austin TX, US
Ralph McDade - Austin TX, US

Assignee:

Rules-Based Medicine, Inc. - Austin TX

International Classification:

G01N033/48

US Classification:

422072000, 436063000

Abstract:

A biochemical image is derived from specimens, preferably obtained from a statistically relevant sample of a subject population sharing a common characteristic. The biochemical images for one or more conditions present in the subject population and/or one or more test subjects are determined and made available for computer implemented diagnostic evaluations and medical research. In addition to using the information for general research purposes, information from the images may be used to classify diseases and disease states.

US Patent:

20050221363, Oct 6, 2005

Filed:

Mar 31, 2005

Appl. No.:

11/094366

Inventors:

Michael Spain - Austin TX, US
Mark Chandler - Austin TX, US

Assignee:

Rules-Based Medicine, Inc. - Austin TX

International Classification:

C12Q001/68
G01N033/53

US Classification:

435006000, 435007100

Abstract:

A method for the multiplexed diagnosis of a plurality of different biomolecules in a fluid sample substantially simultaneously is provided. In accordance with a method of the invention, a substantial fraction of biomolecules in a fluid sample are complexed with a universal label and a secondary labeling reagent. Flow cytometric measurements may be used to identify and quantify, in real-time, by detecting the secondary reagent and universal label present in any of said complexes. The inventive technology enables the simultaneous, and automated, detection and interpretation of multiple biomolecules while also reducing the cost of performing diagnostic and genetic assays.

US Patent:

20070003981, Jan 4, 2007

Filed:

Jun 27, 2006

Appl. No.:

11/475249

Inventors:

Mark Chandler - Austin TX, US
Michael Spain - Austin TX, US
James Mapes - Austin TX, US
George Rodgers - Austin TX, US

International Classification:

G01N 33/53
C12Q 1/37

US Classification:

435007100, 435023000

Abstract:

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

US Patent:

20080020475, Jan 24, 2008

Filed:

May 4, 2007

Appl. No.:

11/744723

Inventors:

Jim Mapes - Austin TX, US
Michael Spain - Austin TX, US
Ralph McDade - Austin TX, US
Kenneth Pass - Glenmont NY, US

International Classification:

G01N 33/53
G06F 15/18

US Classification:

436087000, 706013000

Abstract:

Provided are methods for the detection and diagnosis of Hypothyroidism. The methods are based on the discovery that altered levels of selected analytes in sample fluid, typically blood samples, of patients are supportive of a diagnosis of Hypothyroidism. At least twenty-four new biomarkers for hypothyroidism are thus disclosed (singly or in any combination), Thyroid Stimulating Hormone, Interleukin-12p40, Tumor Necrosis Factor Alpha, Tissue Factor, Interleukin-15, Insulin, Immunoglobulin E, Growth Stimulating Hormone, Calcitonin, Prostate-Specific Antigen, Interleukin-4, Granulocyte Macrophage Colony Stimulating Factor, Matrix Metalloproteinase 9, Lymphotactin, Fatty Acid Binding Protein, Alpha Fetoprotein, Alpha-2 Macroglobulin, Serum Glutamic Oxaloacetic Transaminase, Matrix Metalloproteinase 3, Cancer Antigen 125, Mumps Antibody, Double Stranded DNA Antibody, Proliferating Cell Nuclear Antigen Antibody, Smith Antibody, or Herpes Simplex Virus 1 Glycoprotein D Antibody. Altogether the concentrations of one or more of these analytes, as well as Thyroid Stimulating Hormone, or any combination thereof, provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from Hypothyroidism. Kits containing reagents to assist in the analysis of fluid samples are also described.

US Patent:

20080255766, Oct 16, 2008

Filed:

Feb 7, 2008

Appl. No.:

12/068518

Inventors:

Michael Spain - Austin TX, US
James P. Mapes - Austin TX, US
Ralph L. McDade - Austin TX, US
Kenneth Pass - Glenmont NY, US

International Classification:

G01N 33/53
C12Q 1/00

US Classification:

702 19, 435 4, 435 71

Abstract:

Provided are methods for the detection and diagnosis of sickle cell. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of sickle cell. At least two new biomarkers for sickle cell are thus disclosed, Eotaxin and Monocyte Chemotactic Protein-1. Altogether the concentrations of eleven analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from sickle cell. Other important biomarkers for sickle cell are described, including but not limited to IL-12p40, SHBG, MMP-9, Adiponectin, Haptoglobin, FGF basic, IgM, Growth Hormone, Factor VII. Kits containing reagents to assist in the analysis of fluid samples are also described.